Knightsbridge Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.09M Sell
1,804
-5
-0.3% -$5.9K 0.24% 66
2026
Q2
$2.17M Buy
1,809
+17
+0.9% +$17.4K 0.28% 60
2026
Q1
$1.65M Buy
1,792
+189
+12% +$192K 0.22% 61
2025
Q4
$1.72M Buy
1,603
+49
+3% +$46.9K 0.28% 61
2025
Q3
$1.19M Buy
1,554
+77
+5% +$57.3K 0.2% 67
2025
Q2
$1.15M Buy
1,477
+579
+64% +$450K 0.25% 61
2025
Q1
$741K Buy
898
+85
+10% +$70.7K 0.19% 68
2024
Q4
$628K Buy
813
+15
+2% +$12.4K 0.15% 82
2024
Q3
$707K Buy
798
+98
+14% +$88.1K 0.16% 70
2024
Q2
$634K Buy
700
+4
+0.6% +$3.2K 0.16% 67
2024
Q1
$406K Hold
696
– – 0.11% 83
2023
Q4
$406K Sell
696
-22
-3% -$12.8K 0.11% 83
2023
Q3
$386K Buy
718
+24
+3% +$12.4K 0.12% 84
2023
Q2
$326K Sell
694
-693
-50% -$291K 0.1% 88
2023
Q1
$477K Buy
1,387
+308
+29% +$104K 0.08% 97
2022
Q4
$395K Buy
1,079
+282
+35% +$100K 0.07% 105
2022
Q3
$258K Buy
+797
New +$253K 0.05% 99

Other funds holding LLY

Knightsbridge Asset Management's LLY Position: Q3 2026 in Review

Knightsbridge Asset Management reduced its Eli Lilly (LLY) stake by 0.28% in Q3 2026, selling an estimated $5.9K and leaving 1,804 shares worth $2.09M. The position accounts for 0.24% of the portfolio, ranked #66.

Knightsbridge Asset Management first reported a position in LLY in Q3 2022 and has held it in 17 quarters since. The position peaked at $2.17M in Q2 2026. 4,550 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Knightsbridge Asset Management held 1,804 shares of Eli Lilly worth $2.09M as of Q3 2026.
  • Knightsbridge Asset Management sold 5 Eli Lilly shares in Q3 2026, an estimated $5.9K.
  • Eli Lilly made up 0.24% of Knightsbridge Asset Management's portfolio in Q3 2026, its #66 holding.
  • Knightsbridge Asset Management first reported a position in Eli Lilly in Q3 2022 and has held it in 17 quarters since.
  • Knightsbridge Asset Management's Eli Lilly position peaked at $2.17M in Q2 2026.
  • 4,550 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Knightsbridge Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.